PURPOSE: Lung cancer is the leading cause of cancer-related death worldwide. The efficacy of current systemic treatments is limited, with major side effects and only modest survival improvements. Aerosols routinely used to deliver drugs into the lung for treating infectious and inflammatory lung diseases have never been used to deliver monoclonal antibodies to treat lung cancer. We have shown that cetuximab, a chimeric anticancer anti-EGFR mAb, is suitable for airway delivery as it resists the physical constraints of aerosolization, and have evaluated the aerosol delivery of cetuximab in vivo. METHODS: We developed an animal model of lung tumor sensitive to cetuximab by injecting Balb/c Nude mice intratracheally with A431 cells plus 10 mM EDTA and analyzed the distribution, pharmacokinetics and antitumor efficacy of cetuximab aerosolized into the respiratory tract. RESULTS: Aerosolized IgG accumulated durably in the lungs and the tumor, but passed poorly and slowly into the systemic circulation. Aerosolized cetuximab also limited the growth of the mouse tumor. Thus, administering anticancer mAbs via the airways is effective and may limit systemic side effects. CONCLUSION: Delivery of aerosolized-mAbs via the airways deserves further evaluation for treating lung cancers.
PURPOSE:Lung cancer is the leading cause of cancer-related death worldwide. The efficacy of current systemic treatments is limited, with major side effects and only modest survival improvements. Aerosols routinely used to deliver drugs into the lung for treating infectious and inflammatory lung diseases have never been used to deliver monoclonal antibodies to treat lung cancer. We have shown that cetuximab, a chimeric anticancer anti-EGFR mAb, is suitable for airway delivery as it resists the physical constraints of aerosolization, and have evaluated the aerosol delivery of cetuximab in vivo. METHODS: We developed an animal model of lung tumor sensitive to cetuximab by injecting Balb/c Nude mice intratracheally with A431 cells plus 10 mM EDTA and analyzed the distribution, pharmacokinetics and antitumor efficacy of cetuximab aerosolized into the respiratory tract. RESULTS: Aerosolized IgG accumulated durably in the lungs and the tumor, but passed poorly and slowly into the systemic circulation. Aerosolized cetuximab also limited the growth of the mousetumor. Thus, administering anticancer mAbs via the airways is effective and may limit systemic side effects. CONCLUSION: Delivery of aerosolized-mAbs via the airways deserves further evaluation for treating lung cancers.
Authors: F Gagnadoux; A L Pape; E Lemarié; S Lerondel; I Valo; V Leblond; J-L Racineux; T Urban Journal: Eur Respir J Date: 2005-10 Impact factor: 16.671
Authors: M N Saleh; K P Raisch; M A Stackhouse; W E Grizzle; J A Bonner; M S Mayo; H G Kim; R F Meredith; R H Wheeler; D J Buchsbaum Journal: Cancer Biother Radiopharm Date: 1999-12 Impact factor: 3.099
Authors: S Lerondel; A Le Pape; C Sené; L Faure; S Bernard; P Diot; E Nicolis; M Mehtali; M Lusky; G Cabrini; A Pavirani Journal: Hum Gene Ther Date: 2001-01-01 Impact factor: 5.695
Authors: Victor H Leyva-Grado; Gene S Tan; Paul E Leon; Mark Yondola; Peter Palese Journal: Antimicrob Agents Chemother Date: 2015-05-04 Impact factor: 5.191
Authors: Christina Cortez-Jugo; Aisha Qi; Anushi Rajapaksa; James R Friend; Leslie Y Yeo Journal: Biomicrofluidics Date: 2015-04-08 Impact factor: 2.800
Authors: Davide Corti; Jincun Zhao; Mattia Pedotti; Luca Simonelli; Sudhakar Agnihothram; Craig Fett; Blanca Fernandez-Rodriguez; Mathilde Foglierini; Gloria Agatic; Fabrizia Vanzetta; Robin Gopal; Christopher J Langrish; Nicholas A Barrett; Federica Sallusto; Ralph S Baric; Luca Varani; Maria Zambon; Stanley Perlman; Antonio Lanzavecchia Journal: Proc Natl Acad Sci U S A Date: 2015-07-27 Impact factor: 11.205